Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres

Oncogene volume 34, pages 2309–2316 (2015)Cite this article

Subjects

Abstract

Crosstalk between estrogen receptor (ER) and the inflammatory nuclear factor κB (NFκB) pathway in ER+ breast cancers may contribute to a more aggressive phenotype. Pleckstrin Homology-Like Domain, Family A, member 1 (PHLDA1), a target gene of ER-NFκB crosstalk, has been implicated in cell survival and stem cell properties. 17β-estradiol (E2), acting through ERα, and pro-inflammatory cytokines, acting through NFκB, increase the nascent transcript and PHLDA1 messenger RNA stability, indicating both transcriptional and post-transcriptional control of PHLDA1 expression. We show that PHLDA1 is a direct target of miR-181 and that mature miR-181a and b, as well as their host gene, are synergistically downregulated by E2 and tumor necrosis factor α, also in an ER- and NFκB-dependent manner. Thus, ER and NFκB work together to upregulate PHLDA1 directly through enhanced transcription and indirectly through repression of miR-181a and b. Previous studies have suggested that PHLDA1 may be a stem cell marker in the human intestine that contributes to tumorigenesis. Our findings that PHLDA1 is upregulated in mammospheres (MS) of ER+ breast cancer cells and that PHLDA1 knockdown impairs both MS formation and the expansion of aldehyde dehydrogenase (ALDH)-positive population, suggest that PHLDA1 may play a similar role in breast cancer cells. Upregulation of PHLDA1 in MS is largely dependent on the NFκB pathway, with downregulated miR-181 expression a contributing factor. Over-expression of miR-181 phenocopied PHLDA1 knockdown and significantly impaired MS formation, which was reversed, in part, by protection of the PHLDA1 3′ untranslated region (UTR) or overexpression of PHLDA1 lacking the 3′UTR. Furthermore, we find that elevated PHLDA1 expression is associated with a higher risk of distant metastasis in ER+ breast cancer patients. Altogether, these data suggest that high PHLDA1 expression is controlled through an ER-NFκB-miR-181 regulatory axis and may contribute to a poor clinical outcome in patients with ER+ breast tumors by enhancing stem-like properties in these tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 2005; 37: 1130–1144.

    Article  CAS  Google Scholar 

  2. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007; 7: 59.

    Article  Google Scholar 

  3. Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM et al. Nuclear NF-kappaB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol 2011; 64: 130–135.

    Article  Google Scholar 

  4. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004; 15: 885–890.

    Article  CAS  Google Scholar 

  5. Riggins RB, Zwart A, Nehra R, Clarke R . The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 2005; 4: 33–41.

    Article  CAS  Google Scholar 

  6. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 2009; 69: 8918–8925.

    Article  CAS  Google Scholar 

  7. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J . Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Cancer 2010; 1: 127–135.

    Article  CAS  Google Scholar 

  8. Toyoshima Y, Karas M, Yakar S, Dupont J, Lee H, LeRoith D . TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem 2004; 279: 25898–25904.

    Article  CAS  Google Scholar 

  9. Sakthianandeswaren A, Christie M, D'Andreti C, Tsui C, Jorissen RN, Li S et al. PHLDA1 expression marks the putative epithelial stem cells and contributes to intestinal tumorigenesis. Cancer Res 2011; 71: 3709–3719.

    Article  CAS  Google Scholar 

  10. Van Laere S, Limame R, Van Marck EA, Vermeulen PB, Dirix LY . Is there a role for mammary stem cells in inflammatory breast carcinoma?: a review of evidence from cell line, animal model, and human tissue sample experiments. Cancer 2010; 116: 2794–2805.

    Article  CAS  Google Scholar 

  11. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499–507.

    Article  CAS  Google Scholar 

  12. Choi WY, Giraldez AJ, Schier AF . Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 2007; 318: 271–274.

    Article  CAS  Google Scholar 

  13. Bridge G, Monteiro R, Henderson S, Emuss V, Lagos D, Georgopoulou D et al. The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. Blood 2012; 120: 5063–5072.

    Article  CAS  Google Scholar 

  14. Kim K, Madak-Erdogan Z, Ventrella R, Katzenellenbogen BS . A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-alpha and ERK2 that controls breast cancer proliferation and invasiveness properties. Horm Cancer 2013; 4: 78–91.

    Article  CAS  Google Scholar 

  15. Knauss JL, Bian S, Sun T . Plasmid-based target protectors allow specific blockade of miRNA silencing activity in mammalian developmental systems. Front Cell Neurosci 2013; 7: 163.

    Article  Google Scholar 

  16. Makino K, Jinnin M, Aoi J, Hirano A, Kajihara I, Makino T et al. Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts. J Invest Dermatol 2013; 133: 110–119.

    Article  CAS  Google Scholar 

  17. Ouyang YB, Lu Y, Yue S, Giffard RG . miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 2012; 12: 213–219.

    Article  CAS  Google Scholar 

  18. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Benes V et al. Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 2009; 69: 8332–8340.

    Article  CAS  Google Scholar 

  19. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506–5511.

    Article  CAS  Google Scholar 

  20. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS . Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008; 75: 75–84.

    Article  Google Scholar 

  21. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672–679.

    Article  CAS  Google Scholar 

  22. O'Brien CS, Howell SJ, Farnie G, Clarke RB . Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia 2009; 14: 45–54.

    Article  Google Scholar 

  23. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339–9344.

    Article  CAS  Google Scholar 

  24. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780–783.

    Article  CAS  Google Scholar 

  25. Murohashi M, Hinohara K, Kuroda M, Isagawa T, Tsuji S, Kobayashi S et al. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br J Cancer 2010; 102: 206–212.

    Article  CAS  Google Scholar 

  26. Cao Y, Luo JL, Karin M . IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA 2007; 104: 15852–15857.

    Article  CAS  Google Scholar 

  27. Iliopoulos D, Hirsch HA, Struhl K . An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139: 693–706.

    Article  CAS  Google Scholar 

  28. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45–55.

    Article  CAS  Google Scholar 

  29. Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA 2010; 107: 21737–21742.

    Article  CAS  Google Scholar 

  30. Baumgarten SC, Frasor J . Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 2012; 26: 360–371.

    Article  CAS  Google Scholar 

  31. Pradhan M, Baumgarten SC, Bembinster LA, Frasor J . CBP mediates NF-kappaB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter. Mol Cell Biol 2012; 32: 569–575.

    Article  CAS  Google Scholar 

  32. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J . Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem 2010; 285: 31100–31106.

    Article  CAS  Google Scholar 

  33. Frasor J, Weaver AE, Pradhan M, Mehta K . Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines. Endocrinology 2008; 149: 6272–6279.

    Article  CAS  Google Scholar 

  34. Meier-Noorden M, Flindt S, Kalinke U, Hinz T . A CpG-rich bidirectional promoter induces the T-cell death-associated gene 51 and downregulates an inversely oriented transcript during early T-cell activation. Gene 2004; 338: 197–207.

    Article  CAS  Google Scholar 

  35. Croker AK, Allan AL . Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008; 12: 374–390.

    Article  CAS  Google Scholar 

  36. Velasco-Velazquez MA, Popov VM, Lisanti MP, Pestell RG . The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol 2011; 179: 2–11.

    Article  CAS  Google Scholar 

  37. Hollier BG, Evans K, Mani SA . The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009; 14: 29–43.

    Article  Google Scholar 

  38. Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S et al. PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci 2011; 124: 2711–2722.

    Article  CAS  Google Scholar 

  39. Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP . TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 2013; 123: 150–163.

    Article  CAS  Google Scholar 

  40. Neel JC, Lebrun JJ . Activin and TGFbeta regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. Cell Signal 2013; 25: 1556–1566.

    Article  CAS  Google Scholar 

  41. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013; 12: 1679–1687.

    Article  CAS  Google Scholar 

  42. Lobry C, Oh P, Mansour MR, Look AT, Aifantis I . Notch signaling: switching an oncogene to a tumor suppressor. Blood 2014; 123: 2451–2459.

    Article  CAS  Google Scholar 

  43. Thorner AR, Parker JS, Hoadley KA, Perou CM . Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS ONE 2010; 5: e13073.

    Article  Google Scholar 

  44. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253–1270.

    Article  CAS  Google Scholar 

  45. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645–659.

    Article  CAS  Google Scholar 

  46. Seiler CY, Park JG, Sharma A, Hunter P, Surapaneni P, Sedillo C et al. DNASU plasmid and PSI:Biology-Materials repositories: resources to accelerate biological research. Nucleic Acids Res 2014; 42: D1253–D1260.

    Article  CAS  Google Scholar 

  47. Cormier CY, Park JG, Fiacco M, Steel J, Hunter P, Kramer J et al. PSI:Biology-materials repository: a biologist's resource for protein expression plasmids. J Struct Funct Genomics 2011; 12: 55–62.

    Article  CAS  Google Scholar 

  48. Cormier CY, Mohr SE, Zuo D, Hu Y, Rolfs A, Kramer J et al. Protein Structure Initiative Material Repository: an open shared public resource of structural genomics plasmids for the biological community. Nucleic Acids Res 2010; 38: D743–D749.

    Article  CAS  Google Scholar 

  49. Yang X, Boehm JS, Yang X, Salehi-Ashtiani K, Hao T, Shen Y et al. A public genome-scale lentiviral expression library of human ORFs. Nat Methods 2011; 8: 659–661.

    Article  CAS  Google Scholar 

  50. Gyorffy B, Lanczky A, Szallasi Z . Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012; 19: 197–208.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Shuangping Zhao, Bryant Marure and Tuan-Ahn Tran for technical assistance. We are grateful for the financial support provided by the National Institute of Health (R01 CA130932-05 to JF), the University of Illinois at Chicago through the Chancellor’s Discovery Fund (JF), and by a postdoctoral fellowship grant from Susan G Komen for the Cure to IK (PDF12229484).

Author information

Authors and Affiliations

  1. Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL, USA

    I Kastrati, E Canestrari & J Frasor

Authors
  1. I Kastrati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Canestrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Frasor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Frasor.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kastrati, I., Canestrari, E. & Frasor, J. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres. Oncogene 34, 2309–2316 (2015). https://doi.org/10.1038/onc.2014.180

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2014.180

This article is cited by

Search

Advanced search

Quick links